• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Universal Screening on Admission to Labor Floor: Latest COVID-19 Prevalence Results

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • Many hospitals have implemented universal COVID-19 screening for all women admitted for delivery
  • An NYC health system found a 13.5% prevalence of infection in asymptomatic women early in the pandemic
  • Miller et al. (Obstetrics & Gynecology, 2020) examined the prevalence rates of infection with universal screening in Chicago

METHODS:

  • Prospective case series
  • Setting
    • Chicago hospital system (April 8 to April 27, 2020)
    • Acceleration phase of the pandemic
  • Participants
    • Pregnant women
    • Admitted to the hospital for delivery
  • Study design
    • Universal COVID-19 testing for delivery: Implemented April 8
    • Scheduled deliveries:  Tested 12 to 36 hours before admission 8 hour turnaround time
    • Unscheduled deliveries: Tested in triage | 2 hour turnaround time
    • All women asked about possible COVID-19 symptoms at time of admission
  • Management protocols
    • Positive test: Managed in a dedicated COVID-19 unit
    • Asymptomatic: Managed on routine labor floor | Health care workers used PPE until the test result available
    • Patients and one allowed support person received procedure masks on arrival
    • Support persons screened for symptoms but not tested

RESULTS:

  • Total of 635 pregnant
  • Test results
    • Positive for SARS-CoV-2: 3.6% (23 women)
      • Positive but asymptomatic on presentation: 43.5% (10 women)
  • Symptoms on presentation
    • Reported symptoms on presentation: 3.3% (21 women)
      • Positive for COVID-19: 61.9% (13 women)
    • Did not report symptoms on presentation: 96.7% (614 women)
      • Positive for COVID-19: 1.6% (10 women)

CONCLUSION:

  • Symptoms alone did not reliably identify pregnant women with COVID-19 on admission to labor and delivery units
    • In this study, positive test rates were higher than those reported in the general population, leading the authors to suggest that infection rates in the general population, where testing is generally limited to symptomatic patients, may be higher
  • Sutton et al. (NEJM, 2020) in a similar paper also found a much higher prevalence of infection with universal screening of pregnant women admitted for delivery in NYC
    • 215 pregnant women (all were screened)
    • Symptomatic: 1.9% | All were positive on testing
    • Asymptomatic women: 99.5% | 13.7% positive on testing
    • 87.9% of women had no symptoms of Covid-19 at presentation
  • The authors in the NEJM paper conclude that

The potential benefits of a universal testing approach include the ability to use Covid-19 status to determine hospital isolation practices and bed assignments, inform neonatal care, and guide the use of personal protective equipment

Access to such clinical data provides an important opportunity to protect mothers, babies, and health care teams during these challenging times

Learn More – Primary Sources:

Clinical Implications of Universal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Pregnancy

Universal Screening for SARS-CoV-2 in Women Admitted for Delivery

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Labor & Delivery: Asymptomatic Patients and Universal COVID-19 Testing
Universal Screening: What Percent of Women Admitted to L&D are Positive for SARS-CoV-2?
Comparing SARS-CoV-2 Positive Rates Among Pregnant vs Non-Pregnant Patients in New York State

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site